Related Experiment Videos
Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas
Ana Fernandez-Teijeiro1, Rebecca A Betensky, Lisa M Sturla
1Division of Neuroscience, Department of Neurology, Department of Medicine, Children's Hospital, 300 Longwood Ave, Boston MA 02115, USA.
Summary
Gene expression profiling accurately predicts medulloblastoma patient outcomes. Clinical factors did not improve these predictions, highlighting the importance of molecular markers for risk stratification in pediatric brain tumors.
Area of Science:
- Oncology
- Genomics
- Pediatric Medicine
Background:
- Accurate risk stratification is crucial for medulloblastoma treatment.
- Clinical parameters alone are insufficient for precise disease risk assessment.
- Molecular markers, particularly gene expression profiles, show promise for improved outcome prediction.
Purpose of the Study:
- To evaluate if clinical parameters enhance survival predictions derived from gene expression profiles in medulloblastoma patients.
- To assess the independent predictive value of gene expression profiles versus clinical variables.
Main Methods:
- A cohort of 55 young medulloblastoma patients was analyzed.
- Cox proportional hazards models were used to assess associations between clinical variables, gene expression, and survival.
- Clinical variables included age, stage, sex, histology, treatment, and status.
Main Results:
- Gene expression profiles were the sole significant prognostic factor in univariate analysis (P=.03).
- In multivariate analysis, gene expression profiles independently predicted outcome.
- Clinical criteria did not significantly add predictive information to gene expression profiles.
Conclusions:
- Gene expression profiling is a robust predictor of medulloblastoma outcome, independent of clinical variables.
- Further validation in larger, prospective studies is warranted to confirm these findings.